As European markets grapple with geopolitical uncertainties and inflation, the pan-European STOXX Europe 600 Index has recently dipped by 0.85%. This downturn mirrors widespread concerns across the continent. Nevertheless, solid growth in corporate earnings has emerged, offering possible avenues for investors looking for stocks that may be undervalued. In this scenario, pinpointing stocks trading beneath their intrinsic value can offer notable investment opportunities.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Technip Energies (ENXTPA:TE) | €36.06 | €70.50 | 48.8% |
| Revenio Group Oyj (HLSE:REG1V) | €14.06 | €28.02 | 49.8% |
| Netcompany Group (CPSE:NETC) | DKK338.20 | DKK676.21 | 50% |
| Icelandic Salmon (OB:ISLAX) | NOK75.50 | NOK150.28 | 49.8% |
| F-Secure Oyj (HLSE:FSECURE) | €1.888 | €3.75 | 49.7% |
| doValue (BIT:DOV) | €2.23 | €4.40 | 49.3% |
| Cint Group (OM:CINT) | SEK5.91 | SEK11.57 | 48.9% |
| Cavotec Group (OM:CCC) | SEK13.35 | SEK26.59 | 49.8% |
| B&S Group (ENXTAM:BSGR) | €5.85 | €11.66 | 49.8% |
| Ambu (CPSE:AMBU B) | DKK66.35 | DKK131.51 | 49.5% |
Explore some notable selections from the results of our screener.
Overview: BioGaia AB is a healthcare firm dedicated to developing and selling probiotic products aimed at enhancing gut, oral, and immune health across various regions, including Europe and the U.S., with a market cap of SEK13.65 billion.
Operations: Revenue is generated from the creation and distribution of probiotic products that cater to gut, oral, and immune health.
Estimated Discount To Fair Value: 22.8%
BioGaia is currently trading at SEK 134.9, which is below its anticipated cash flow valuation of SEK 174.71. Although Q1 sales showed a modest growth to SEK 372.55 million, net income remained stable. Earnings are projected to grow by 18.2% annually, exceeding Swedish market expectations. However, a 2.97% dividend yield may face sustainability challenges against free cash flows, despite forecasts of strong revenue bolstered by innovative products like LongevityGuard technology.
